Overview


According to FutureWise analysis, the market for Mosquito Borne Disease is expected to grow with a CAGR of 7.52% over the forecast period 2024-2032, and reach a market value of US$ 5.5 Billion by 2031. 

Mosquito-borne diseases encompass various infectious illnesses transmitted to humans, mainly through the bites of infected mosquitoes. These diseases stem from multiple pathogens, including viruses, bacteria, and parasites, which the mosquitoes acquire when feeding infected hosts. Among the most prevalent mosquito-borne diseases are malaria, dengue fever, Zika virus, chikungunya, and West Nile virus. Malaria, caused by Plasmodium parasites, is one of the most lethal mosquito-borne diseases globally, particularly rampant in tropical and subtropical regions. It manifests with symptoms like fever, chills, and fatigue, which can lead to severe complications if not promptly treated. Dengue fever, resulting from the dengue virus, is characterized by symptoms including high fever, severe headaches, and joint and muscle pain. In extreme cases, it can progress to dengue haemorrhagic fever or dengue shock syndrome, potentially culminating in fatality.

Preventing mosquito-borne diseases necessitates a multifaceted approach involving vector control methods, such as mosquito repellents, insecticide-treated bed nets, and indoor residual spraying. Personal protective measures are also crucial, such as employing insect repellent, wearing long-sleeved clothing, and ensuring proper sanitation to eliminate breeding sites. The comprehensive tackling of these diseases calls for a collaborative effort involving healthcare, public health initiatives, and active community engagement.

FutureWise Market Research has published a report that provides an insightful analysis of Mosquito Borne Disease Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Mosquito Borne Disease Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Johnson & Johnson
  • Eisai Co., Ltd
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca
  • Valeant Pharmaceuticals International, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Abbott
  • Hoffmann-La Roche Ltd
  • Sun Pharmaceutical Industries Ltd
  • Lupin Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Mallinckrodt Pharmaceuticals
  • Serum Institute of India Pvt. Ltd.
  • CSL Limited
  • Teva Pharmaceutical Industries Ltd

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Mosquito Borne Disease Market:

  • In July 2022, GSK revealed that the European Medicines Agency (EMA) had approved Mosquirix, marking the first-ever malaria vaccine. Mosquirix specifically targets plasmodium falciparum malaria, which is highly prevalent in Africa. This breakthrough vaccine holds the promise of potentially saving numerous lives.

  • In June 2021, Bharat Biotech introduced a Chikungunya vaccine under the name Chikungunya Vacc-DCV in India. This vaccine can alleviate the burden of Chikungunya disease in India and worldwide.

The increasing incidence and spread of malaria, dengue, Zika, and others in various regions drive the demand for effective prevention, diagnosis, and treatment. Growing awareness about the impact of mosquito-borne diseases and proactive measures by governments and international organizations to combat these diseases contribute to market growth. Ongoing research and development efforts lead to the introduction of more accurate diagnostic tools, advanced treatments, and innovative vector control measures. Higher healthcare spending globally enables the development of better healthcare infrastructure, research, and access to effective interventions for mosquito-borne diseases. Changes in climate patterns and increased urbanization can lead to expanded habitats for disease-carrying mosquitoes, contributing to a higher prevalence of these diseases. Collaborations between governments, non-profit organizations, and pharmaceutical companies can lead to increased funding, research, and development of new interventions, bolstering market growth.

However, the emergence of drug-resistant strains of pathogens, particularly in malaria, poses a significant challenge to effective treatment. The investment required to develop new drugs, vaccines, and diagnostic tools can be substantial, potentially limiting the number of market entrants. Stringent regulatory approval processes and compliance standards for new drugs and vaccines can slow the introduction of innovative solutions, hampering market growth.

By Disease Type

  • Malaria
  • Dengue
  • Yellow Fever
  • West Nile Virus
  • Chikungunya
  • Zika Virus
  • Others

By Treatment Type

  • Medication
  • Vaccination
  • Vector Control Methods
  • Immunotherapy
  • Supportive Care
  • Others

By End User

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Research Institutes
  • Government Organizations
  • NGOs
  • Others

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to increased awareness, access to advanced treatments, presence of leading healthcare companies, and strong government support for the elimination of mosquito-borne diseases. Conversely, the Asia-Pacific region is poised for substantial expansion in the forecast period due to high disease burden, tropical climate suiting mosquito growth, improving healthcare infrastructure, and rising healthcare expenditure.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Mosquito Borne Disease Market By Disease Type, By Treatment Type, By End User, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Mosquito Borne Disease Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Mosquito Borne Disease Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Mosquito Borne Disease Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Mosquito Borne Disease Market, By Disease Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Malaria
        2. Dengue
        3. Yellow Fever
        4. West Nile Virus
        5. Chikungunya
        6. Zika Virus
        7. Others

  • 8.  Mosquito Borne Disease Market, By Treatment Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Medication
        2. Vaccination
        3. Vector Control Methods
        4. Immunotherapy
        5. Supportive Care
        6. Others

  • 9.  Mosquito Borne Disease Market, By End User Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Diagnostic Centers
        4. Research Institutes
        5. Government Organizations
        6. NGOs
        7. Others

  • 10.  North America Mosquito Borne Disease Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.  Latin America Mosquito Borne Disease Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.  Europe Mosquito Borne Disease Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.  Asia Pacific Mosquito Borne Disease Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032  

  • 14.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. GlaxoSmithKline plc
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Sanofi S.A.
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Pfizer Inc.
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Merck & Co., Inc.
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Novartis AG
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Johnson & Johnson
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Eisai Co., Ltd
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Takeda Pharmaceutical Company Limited
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. AstraZeneca
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Valeant Pharmaceuticals International, Inc.
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. Mitsubishi Tanabe Pharma Corporation
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Abbott
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. Hoffmann-La Roche Ltd
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview
        14. Sun Pharmaceutical Industries Ltd
           14.1. Company Overview
           14.2. Product Portfolio
           14.3. SWOT Analysis
           14.4. Financial Overview
           14.5. Strategic Overview
        15. Lupin Pharmaceuticals, Inc.
           15.1. Company Overview
           15.2. Product Portfolio
           15.3. SWOT Analysis
           15.4. Financial Overview
           15.5. Strategic Overview
        16. BioCryst Pharmaceuticals, Inc.
           16.1. Company Overview
           16.2. Product Portfolio
           16.3. SWOT Analysis
           16.4. Financial Overview
           16.5. Strategic Overview
        17. Mallinckrodt Pharmaceuticals
           17.1. Company Overview
           17.2. Product Portfolio
           17.3. SWOT Analysis
           17.4. Financial Overview
           17.5. Strategic Overview
        18. Serum Institute of India Pvt. Ltd.
           18.1. Company Overview
           18.2. Product Portfolio
           18.3. SWOT Analysis
           18.4. Financial Overview
           18.5. Strategic Overview
        19. CSL Limited
           19.1. Company Overview
           19.2. Product Portfolio
           19.3. SWOT Analysis
           19.4. Financial Overview
           19.5. Strategic Overview
        20. Teva Pharmaceutical Industries Ltd
           20.1. Company Overview
           20.2. Product Portfolio
           20.3. SWOT Analysis
           20.4. Financial Overview
           20.5. Strategic Overview

  • 17.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients